MSB 2.67% 96.0¢ mesoblast limited

MSB 2022 - The road to commercialisation, page-603

  1. 7,920 Posts.
    lightbulb Created with Sketch. 627
    Mate are you paying attention
    1 You stated there should have been an RCT with SOC as the placebo
    2 I pointed out that no parent would enrol in the trial as the placebo was a certain death sentence
    3 Then the last post is obviously there is a certain SOC which they must be getting

    Let’s start again …Grade 3-4 aGvHD has a mortality rate at present SOC of 85-90% at 180 days
    With Rem-l the mortality rate at 1 year is about 30-35% at over 1 year
    The question you have to ask is it ethical to have a placebo with no cross over for grade 3-4 disease which will mean certain death if you get the short straw
    Last edited by stocksa: 08/05/22
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
96.0¢
Change
0.025(2.67%)
Mkt cap ! $1.096B
Open High Low Value Volume
95.0¢ 96.5¢ 94.0¢ $1.231M 1.291M

Buyers (Bids)

No. Vol. Price($)
4 94461 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
96.0¢ 61151 6
View Market Depth
Last trade - 16.10pm 12/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.